Literature DB >> 10607814

Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies.

G H Lipscomb1, M L McCord, T G Stovall, G Huff, S G Portera, F W Ling.   

Abstract

BACKGROUND: The use of methotrexate for the treatment of women with tubal ectopic pregnancies is now common practice. However, the clinical and hormonal determinants of the success of this treatment are not known.
METHODS: We studied 350 women with tubal ectopic pregnancies who were treated with methotrexate intramuscularly according to a single-dose protocol. Pretreatment serum concentrations of human chorionic gonadotropin and progesterone, the size and volume of the gestational mass, fetal cardiac activity, and the presence of fluid (presumably blood) in the peritoneal cavity were correlated with the efficacy of therapy, as defined by resolution of the ectopic pregnancy without the need for surgical intervention.
RESULTS: There was no relation between the women's age or parity, the size or volume of the conceptus, or the presence of fluid in the peritoneal cavity and the efficacy of treatment. Among the 320 women in whom treatment was successful (91 percent), the mean (+/-SD) serum chorionic gonadotropin and progesterone concentrations were 4019+/-6362 mIU per milliliter and 6.9+/-6.7 ng per milliliter (21.9+/-21.3 nmol per liter), respectively, as compared with 13,420+/-16,590 mIU per milliliter and 10.2+/-5.5 ng per milliliter (32.4+/-17.5 nmol per liter) (P<0.001 and P=0.02) in the 30 women in whom treatment was not successful. Fetal cardiac activity was present in 12 percent of the successfully treated cases and 30 percent of those in which treatment was not successful (P=0.01). Regression analysis revealed the pretreatment serum chorionic gonadotropin concentration to be the only factor that contributed to the failure rate.
CONCLUSIONS: Among women with tubal ectopic pregnancies, a high serum chorionic gonadotropin concentration is the most important factor associated with failure of treatment with a single-dose methotrexate protocol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10607814     DOI: 10.1056/NEJM199912233412604

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

1.  Surveillance in a time of changing health care practices: estimating ectopic pregnancy incidence in the United States.

Authors:  Suzanne B Zane; Burney A Kieke; Juliette S Kendrick; Carol Bruce
Journal:  Matern Child Health J       Date:  2002-12

Review 2.  Tubal ectopic pregnancy.

Authors:  Rajesh Varma; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2012-02-10

3.  Tubal ectopic pregnancy.

Authors:  Vinod Kumar; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2015-11-16

Review 4.  Tubal ectopic pregnancy.

Authors:  Rajesh Varma; Janesh Gupta
Journal:  BMJ Clin Evid       Date:  2009-04-20

5.  The efficacy and safety of managing ectopic pregnancies with transvaginal ultrasound-guided local injections of absolute ethanol.

Authors:  Hirotsune Kaijima; Hisao Osada; Keiichi Kato; Tomoya Segawa; Yuji Takehara; Shokichi Teramoto; Osamu Kato
Journal:  J Assist Reprod Genet       Date:  2006-07-12       Impact factor: 3.412

6.  Failed medical management in ovarian pregnancy despite favorable prognostic factors--a case report.

Authors:  Rashmi Bagga; Vanita Suri; Preeti Verma; Seema Chopra; Jasvinder Kalra
Journal:  MedGenMed       Date:  2006-05-09

7.  Clinical predictors of failing one dose of methotrexate for ectopic pregnancy after in vitro fertilization.

Authors:  Paula C Brady; Stacey A Missmer; Leslie V Farland; Elizabeth S Ginsburg
Journal:  J Assist Reprod Genet       Date:  2017-01-05       Impact factor: 3.412

8.  Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes.

Authors:  Christina E Boots; Micah J Hill; Eve C Feinberg; Ruth B Lathi; Susan A Fowler; Emily S Jungheim
Journal:  J Assist Reprod Genet       Date:  2016-03-04       Impact factor: 3.412

9.  Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success.

Authors:  Ebru Celik; Ilgın Türkçüoğlu; Abdullah Karaer; Pinar Kırıcı; Sevil Eraslan
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

10.  Case report of a primary ovarian pregnancy in a primigravida.

Authors:  Subrat Panda; Laleng M Darlong; Santa Singh; Tulon Borah
Journal:  J Hum Reprod Sci       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.